WASHINGTON (January 28) -- Yesterday, the Centers for Medicare & Medicaid Services announced the third round of drugs subject to Medicare price controls under the Inflation Reduction Act. The new government-set prices will affect medicines covered under both Medicare Part D and Medicare Part B and take effect in 2028. Incubate's executive director, John Stanford, issued the following statement in response: "The latest announcement from CMS represents a significant expan

WASHINGTON ( January 15 ) -- Today, President Trump unveiled his "Great Healthcare Plan," including a proposal for Congress to codify Most Favored Nation (MFN) drug pricing into law. This policy would import foreign government price controls into the U.S. market and threaten the innovation ecosystem responsible for delivering new cures and lifesaving treatments. Incubate's executive director, John Stanford, issued the following statement in response to the announcement:

WASHINGTON ( January 12 ) -- Today, Incubate Policy Lab released insights from a survey of life sciences venture capital (VC) investors showing that policy -- not just scientific potential -- is playing an increasing role in how investors assess biotech opportunities. In other words, VCs aren't just watching the science; they're watching Washington. The VCs surveyed invest in various companies, including early-stage startups and large, publicly traded firms. Respondents poi